Literature DB >> 3102092

Ifosfamide in advanced pancreatic cancer. A 5-year experience.

N Gad-el-Mawla.   

Abstract

Ifosfamide was studied in advanced pancreatic tumor at the National Cancer Institute, Cairo. Over five years, 25 patients received a daily dose of 1.8 g ifosfamide for five days, courses reported every 21 days. Complete remission was achieved in 1 patient and partial remission in 14 patients, an overall result of 60%, average duration of response being 12+ months. Mesna was used for uroprotection.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3102092     DOI： 10.1007/bf00647453

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  1 in total

Review 1.  The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma.

Authors:  S K Carter; R L Comis
Journal:  Cancer Treat Rev       Date:  1975-09       Impact factor: 12.111
  1 in total
  6 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.

Authors:  C I Falkson; H C Falkson; G Falkson
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

3.  Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.

Authors:  T Cerny; G Martinelli; A Goldhirsch; F Terrier; R Joss; M F Fey; K W Brunner; A Küpfer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Ifosfamide treatment as a 10-day continuous intravenous infusion.

Authors:  H J Keizer; J Ouwerkerk; K Welvaart; C J van der Velde; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

5.  Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer.

Authors:  Juraj Hlavaty; Helga Petznek; Harry Holzmüller; Angelika Url; Gerrit Jandl; André Berger; Brian Salmons; Walter H Günzburg; Matthias Renner
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

Review 6.  Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer.

Authors:  J Matthias Löhr; Stephan L Haas; Jens C Kröger; Helmut M Friess; Raimund Höft; Peter E Goretzki; Christian Peschel; Markus Schweigert; Brian Salmons; Walter H Gunzburg
Journal:  Pharmaceutics       Date:  2014-08-11       Impact factor: 6.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.